These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23056531)

  • 1. Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production.
    Lacerda RB; da Silva LL; de Lima CK; Miguez E; Miranda AL; Laufer SA; Barreiro EJ; Fraga CA
    PLoS One; 2012; 7(10):e46925. PubMed ID: 23056531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent imidazo[1,2-a]pyridine-N-Glycinyl-hydrazone inhibitors of TNF-α production: in vitro and in vivo studies.
    Lacerda RB; Sales NM; da Silva LL; Tesch R; Miranda AL; Barreiro EJ; Fernandes PD; Fraga CA
    PLoS One; 2014; 9(3):e91660. PubMed ID: 24632827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazole-hydrazone derivatives as anti-inflammatory agents: Design, synthesis, biological evaluation, COX-1,2/5-LOX inhibition and docking study.
    Abdelgawad MA; Labib MB; Abdel-Latif M
    Bioorg Chem; 2017 Oct; 74():212-220. PubMed ID: 28865292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
    Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
    J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.
    Branger J; van den Blink B; Weijer S; Madwed J; Bos CL; Gupta A; Yong CL; Polmar SH; Olszyna DP; Hack CE; van Deventer SJ; Peppelenbosch MP; van der Poll T
    J Immunol; 2002 Apr; 168(8):4070-7. PubMed ID: 11937566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
    Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
    Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives.
    Khoshneviszadeh M; Ghahremani MH; Foroumadi A; Miri R; Firuzi O; Madadkar-Sobhani A; Edraki N; Parsa M; Shafiee A
    Bioorg Med Chem; 2013 Nov; 21(21):6708-17. PubMed ID: 23993677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.
    Armstrong J; Harbron C; Lea S; Booth G; Cadden P; Wreggett KA; Singh D
    J Pharmacol Exp Ther; 2011 Sep; 338(3):732-40. PubMed ID: 21610141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.
    de Melo TR; Chelucci RC; Pires ME; Dutra LA; Barbieri KP; Bosquesi PL; Trossini GH; Chung MC; dos Santos JL
    Int J Mol Sci; 2014 Apr; 15(4):5821-37. PubMed ID: 24714090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity.
    Chen LZ; Sun WW; Bo L; Wang JQ; Xiu C; Tang WJ; Shi JB; Zhou HP; Liu XH
    Eur J Med Chem; 2017 Sep; 138():170-181. PubMed ID: 28667873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
    de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM
    Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, molecular docking, and biological evaluation of some novel hydrazones and pyrazole derivatives as anti-inflammatory agents.
    Mohammed KO; Nissan YM
    Chem Biol Drug Des; 2014 Oct; 84(4):473-88. PubMed ID: 24720475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates.
    Tributino JL; Duarte CD; Corrêa RS; Doriguetto AC; Ellena J; Romeiro NC; Castro NG; Miranda AL; Barreiro EJ; Fraga CA
    Bioorg Med Chem; 2009 Feb; 17(3):1125-31. PubMed ID: 19135376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.
    Regan J; Breitfelder S; Cirillo P; Gilmore T; Graham AG; Hickey E; Klaus B; Madwed J; Moriak M; Moss N; Pargellis C; Pav S; Proto A; Swinamer A; Tong L; Torcellini C
    J Med Chem; 2002 Jul; 45(14):2994-3008. PubMed ID: 12086485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity of a small molecule indole analog, 1-[(1H-indol-3-yl)methylene]-2-phenylhydrazine (HMPH), in chronic inflammation.
    Misra CS; Gejjalagere Honnappa C; Jitta SR; Gourishetti K; Daram P; Singh MP; Hosur Shrungeswara A; Nayak Y; Unnikrishnan MK
    Chem Biol Interact; 2016 Jan; 244():71-83. PubMed ID: 26549477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SD0006: a potent, selective and orally available inhibitor of p38 kinase.
    Burnette BL; Selness S; Devraj R; Jungbluth G; Kurumbail R; Stillwell L; Anderson G; Mnich S; Hirsch J; Compton R; De Ciechi P; Hope H; Hepperle M; Keith RH; Naing W; Shieh H; Portanova J; Zhang Y; Zhang J; Leimgruber RM; Monahan J
    Pharmacology; 2009; 84(1):42-60. PubMed ID: 19590255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, biological evaluation, and in silico studies of quinoxaline derivatives as potent p38α MAPK inhibitors.
    Anjali ; Kamboj P; Alam O; Patel H; Ahmad I; Ahmad SS; Amir M
    Arch Pharm (Weinheim); 2024 Jan; 357(1):e2300301. PubMed ID: 37847883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.